Boston Scientific Given Neutral Rating at Zacks (BSX)
Boston Scientific (NYSE:BSX)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued on Friday. They currently have a $14.00 price objective on the stock. Zacks‘s price objective indicates a potential upside of 7.78% from the stock’s previous close.
Boston Scientific (NYSE:BSX) traded down 0.77% on Friday, hitting $12.89. The stock had a trading volume of 5,882,593 shares. Boston Scientific has a 1-year low of $8.93 and a 1-year high of $14.08. The stock’s 50-day moving average is $13.03 and its 200-day moving average is $12.77. The company has a market cap of $17.049 billion and a price-to-earnings ratio of 47.58. Boston Scientific also was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 22,700,471 shares, a growth of 12.7% from the April 30th total of 20,139,724 shares. Based on an average daily trading volume, of 11,971,182 shares, the short-interest ratio is presently 1.9 days. Currently, 1.7% of the shares of the company are short sold.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.16 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Analysts expect that Boston Scientific will post $0.81 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Separately, analysts at Citigroup Inc. reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, April 30th. They now have a $13.80 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Boston Scientific from $14.00 to $15.00 in a research note on Wednesday, April 23rd. They now have an “outperform” rating on the stock. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Boston Scientific presently has an average rating of “Buy” and an average target price of $13.57.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.